Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis

Finlay, Andrew Yule ORCID: https://orcid.org/0000-0003-2143-1646, Salek, Mir-saeed and Haney, J. 2003. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 206 (4) , pp. 307-315. 10.1159/000069942

Full text not available from this repository.

Abstract

Psoriasis profoundly affects patient quality of life (QOL). Amevive® (alefacept), a novel and selective biologic agent, was clinically effective and significantly improved QOL in a phase 2 study. Methods: The present placebo-controlled, randomized phase 3 study examined the effects of a 12-week course of intramuscular alefacept on QOL in 507 patients with chronic plaque psoriasis using both dermatology-specific questionnaires [Dermatology Life Quality Index (DLQI); Dermatology Quality of Life Scales (DQOLS)] and the Short Form-36TM Health Survey (SF-36), a generic, general health questionnaire. Results: All 3 QOL measures (DLQI, DQOLS, SF-36) demonstrated that alefacept 15 mg was significantly more effective than placebo in improving QOL in patients with chronic plaque psoriasis. In addition, the improvements in QOL for patients in the alefacept 15 mg group were of similar magnitude for all 3 QOL measures. Conclusion: The findings of this study are an important addition to the QOL literature for psoriasis treatments.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Pharmacy
Subjects:	R Medicine > RL Dermatology R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	Psoriasis ; Alefacept ; Quality of life
Publisher:	Karger
ISSN:	1018-8665
Last Modified:	08 Dec 2022 09:52
URI:	https://orca.cardiff.ac.uk/id/eprint/34229

Citation Data

Cited 84 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item